@Article{Wizner2020,
journal="Lekarz POZ",
issn="2450-3517",
volume="6",
number="4",
year="2020",
title="Effective combination of chronic heart failure and chronic obstructive pulmonary disease pharmacotherapy – is it possible?",
abstract="The article presents the modern pharmacotherapy of coincident two common diagnoses: chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF). From the clinical point of view, the main doubts and controversies are related to β-blockers. Non-selective β-blockers decrease FEV1. The fears of the use of cardioselective β-blockers are unjustified: retrospective observations indicate that they have a neutral or advantageous effect on the decrease of COPD exacerbation frequency. β-blockers may prevent arrhythmogenic and ischaemic incidents during the intensification of inhaled β2-agonist therapy. The highest cardioselectivity is represented by nebivolol. It is deemed that cholinolytics and β2-agonists with prolonged activity cause ventricular and supraventricular arrythmias. However – attention should be paid to other coexisting arrhythmogenic factors: the erroneous use of theophylline, pulmonary embolism, hypokalaemia, hypomagnesaemia, hypoxaemia, chronic kidney disease, and the COPD exacerbation itself. At last magnesium citrate – the element recommended both by heart and lung specialists.",
author="Wizner, Anna
and Szulik, Mariola",
url="https://www.termedia.pl/Effective-combination-of-chronic-heart-failure-and-chronic-obstructive-pulmonary-disease-pharmacotherapy-is-it-possible-,98,42583,1,1.html"
}